Miki K, Yokota S, Hiraga T, Yamaguchi T, Nakagawa M, Maekura R, Ito M, Ogura T
Department of Internal Medicine, Toneyama National Hospital, Osaka, Japan.
Nihon Kokyuki Gakkai Zasshi. 1999 Jan;37(1):31-5.
The clinical effectiveness of isoniazid (INH) inhalation was studied retrospectively in 34 patients with endobronchial tuberculosis. Diagnoses of endobronchial tuberculosis and assessments of bronchial stenosis were based on bronchoscopic examinations. We divided the patients into 2 groups: 13 who received systemic chemotherapy for lung tuberculosis only, and 21 who received systemic chemotherapy combined with INH inhalation (200 mg/day). No significant differences distinguished the groups with respect to duration of positive sputum culture or ESR normalization. However, a significant alleviation of bronchial stenosis and earlier reduction of respiratory symptoms were observed in the patients who received systemic chemotherapy with INH inhalation. We concluded that INH inhalation in addition to standard therapy for lung tuberculosis is effective in patients with endobronchial tuberculosis.
我们对34例支气管内膜结核患者进行回顾性研究，以探讨异烟肼（INH）吸入治疗的临床疗效。支气管内膜结核的诊断及支气管狭窄的评估均基于支气管镜检查。我们将患者分为两组：13例仅接受肺结核全身化疗，21例接受全身化疗联合INH吸入（200mg/天）。两组在痰培养阳性持续时间或血沉恢复正常方面无显著差异。然而，接受全身化疗联合INH吸入的患者支气管狭窄明显缓解，呼吸道症状缓解时间更早。我们得出结论，对于支气管内膜结核患者，在肺结核标准治疗基础上加用INH吸入治疗是有效的。
